Adoptive T Cell Immunotherapy for Cancer
Harnessing the immune system to recognize and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in optimizing this technology in order to make it a clinically feasible treatment. One of the main treatment modalities with...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Rambam Health Care Campus
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327320/ |
| id |
pubmed-4327320 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-43273202015-02-25 Adoptive T Cell Immunotherapy for Cancer Perica, Karlo Varela, Juan Carlos Oelke, Mathias Schneck, Jonathan Cancer Immunotherapy Harnessing the immune system to recognize and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in optimizing this technology in order to make it a clinically feasible treatment. One of the main treatment modalities within cancer immunotherapy has been adoptive T cell therapy (ACT). Using this approach, tumor-specific cytotoxic T cells are infused into cancer patients with the goal of recognizing, targeting, and destroying tumor cells. In the current review, we revisit some of the major successes of ACT, the major hurdles that have been overcome to optimize ACT, the remaining challenges, and future approaches to make ACT widely available. Rambam Health Care Campus 2015-01-29 /pmc/articles/PMC4327320/ /pubmed/25717386 http://dx.doi.org/10.5041/RMMJ.10179 Text en Copyright: © 2015 Perica et al. This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Perica, Karlo Varela, Juan Carlos Oelke, Mathias Schneck, Jonathan |
| spellingShingle |
Perica, Karlo Varela, Juan Carlos Oelke, Mathias Schneck, Jonathan Adoptive T Cell Immunotherapy for Cancer |
| author_facet |
Perica, Karlo Varela, Juan Carlos Oelke, Mathias Schneck, Jonathan |
| author_sort |
Perica, Karlo |
| title |
Adoptive T Cell Immunotherapy for Cancer |
| title_short |
Adoptive T Cell Immunotherapy for Cancer |
| title_full |
Adoptive T Cell Immunotherapy for Cancer |
| title_fullStr |
Adoptive T Cell Immunotherapy for Cancer |
| title_full_unstemmed |
Adoptive T Cell Immunotherapy for Cancer |
| title_sort |
adoptive t cell immunotherapy for cancer |
| description |
Harnessing the immune system to recognize and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in optimizing this technology in order to make it a clinically feasible treatment. One of the main treatment modalities within cancer immunotherapy has been adoptive T cell therapy (ACT). Using this approach, tumor-specific cytotoxic T cells are infused into cancer patients with the goal of recognizing, targeting, and destroying tumor cells. In the current review, we revisit some of the major successes of ACT, the major hurdles that have been overcome to optimize ACT, the remaining challenges, and future approaches to make ACT widely available. |
| publisher |
Rambam Health Care Campus |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327320/ |
| _version_ |
1613187736138678272 |